5am Ventures
- Germany
- France
- Finland
- Denmark
- Sweden
- Italy
- Seed
- Series A
- Series B
- Life Sciences
5AM Ventures is a leading venture capital firm focused on early-stage life sciences companies, primarily investing in seed and Series A rounds. Founded in 2002 and headquartered in San Francisco and Boston, 5AM supports companies developing groundbreaking biopharmaceuticals, drug delivery technologies, and life science instruments, partnering closely with entrepreneurs to translate scientific research into impactful healthcare innovations.
Investment Thesis
Manager's Experience
Team
Kush M Parmar
MD
PhD – Managing Partner
Andy J. Schwab – Managing Partner
Michael Calore – Partner
Head of Investor Relations
John Kelly – Partner
Chief Financial Officer & Chief Operating Officer
Deborah Palestrant
PhD – Partner
Executive Chair
4:59 Initiative
Paul A. Stone
JD – Partner
Chief Legal Officer
Anna Yaeger – Partner
Head of Public Equities
Nicoletta Agostino – Senior Financial Analyst
Lindsay Ziegler Antonio – Compliance Manager
Kamila Bajerski – Assistant Controller
Andrew Booth – Venture Advisor
Rahul Bose – Senior Research Analyst
Jacquelyn Brough
CPA – Senior Vice President
Finance
Caroline Chamales – Senior Executive Assistant
Kevin Corsini Rosewood – Junior Executive Assistant
Office Manager
Lauren Daniel
JD – Chief Compliance Officer and Deputy General Counsel
Brian Daniels
MD – Venture Partner
Gisella de la Rocha
JD – Senior Corporate Counsel
4:59 Initiative
John D. Diekman
PhD – Founding Partner
Britt Inga Emerson – Investor Relations Manager
Max Farina
MD – Principal
Mason Freeman
MD – Venture Partner
Joshua Grass – Venture Partner
Steve Hitchcock
PhD – Venture Partner
Jane Johnstone – Associate Director
Legal
Peter S. Kim
PhD – Venture Advisor
Jennifer Kozub – Operations Manager and Executive Assistant
Elliott Levy
MD – Venture Partner
Jack Liu
PhD – Senior Research Analyst
Joe Loscalzo
MD
PhD – Venture Advisor
Vamsi Mootha
MD – Venture Advisor
Bella Nittolo – Administrative Assistant and Office Manager
Kori Rahaim – Senior Vice President
Head of People and 4:59 Initiative Business Operations
Scott M. Rocklage
PhD – Founding Partner
Paula Soteropoulos – Venture Partner
Katie Bodner Spielberg
PhD – Principal
Brian Stefanowicz
CPA – Controller
Aniqa Tasnim
PhD – Associate
Arthur Tzianabos
PhD – Venture Partner
Joseph J. Victor – Venture Advisor
Jonathan Weissman
PhD – Venture Advisor
Jennifer Zimmermann – Marketing Manager & Executive Assistant
Portfolio
Achaogen (AKAO)
Akouos (AKUS)
Alexza (ALXA)
Ambrx
Aprea (APRE)
Artiva Biotherapeutics (ARTV)
Arvinas (ARVN)
Audentes
Bellerophon (BLPH)
Bird Rock Bio
Cabaletta Bio (CABA)
Calibrium
Camp4 (CAMP)
Cellular Research
Ceterix
Chrono
Cidara (CDTX)
CinCor (CINC)
Crinetics (CRNX)
Dianthus Therapeutics (DNTH)
DVS
Enliven Therapeutics (ELVN)
Ensoma
Entrada (TRDA)
Envoy
Epirus (EPRS)
Escient Pharmaceuticals
Expansion Therapeutics
Flexion (FLXN)
GlycoEra
Halio
Inc.
Homology Medicines
Inc. (FIXX)
Ideaya Biosciences
Igenica
Ikaria
Ilypsa
Impel Neuropharma (IMPL)
Incline
Inipharm
KaloBios (KBIO)
Karius
Kinaset Therapeutics
Latigo
Lifordi
Magnetic Insight
Marcadia
Miikana
Millendo
nChroma Bio
Neurogastrx
Nido Bio
NodThera
Nouscom
Novira
Panomics
Pear (PEAR)
Pearl
PhaseRx (PZRX)
Portal
Precede Bio
PNI
Pulmatrix (PULM)
Purigen
Radionetics
Rallybio (RLYB)
RareCyte
Relypsa (RLYP)
Rennovia
Scientist.com
scPharmaceuticals (SCPH)
Semprus
Skye (SKYE)
Synosia
TMRW
VBI Vaccines
Viveve (VIVE)
Vor Biopharma (VOR)
Wildcat